THERAPEUTICS
Review: faecal occult blood test screening reduces risk of colorectal cancer mortality
| The first 150 words of the full text of this article appear below. |
P Hewitson
Dr P Hewitson, University of Oxford, Headington, UK; paul.hewitson@dphpc.ox.ac.uk
QUESTION
Does faecal occult blood test (FOBT) screening reduce colorectal cancer mortality?
REVIEW SCOPE
Included studies evaluated annual or biennial screening for colorectal cancer with guaiac or immunochemical FOBTs. Outcomes included incidence of colorectal cancer, colorectal cancer mortality, and all-cause mortality.
REVIEW METHODS
Medline, CINAHL, EMBASE/Excerpta Medica, Cochrane Library (Issue 1, 2005), PsycINFO, Allied and Complementary Medicine Database, System of Information on Grey Literature in Europe, Healthcare Management Information Consortium, and reference lists were searched from 1989 to February 2006 for randomised controlled trials (RCTs). 4 RCTs (n = 329 642, age 45–80 y) met the selection criteria. Duration of follow-up was 12–18 years.
MAIN RESULTS
Meta-analysis showed that FOBTs reduced colorectal cancer mortality compared with no screening (table); groups did not differ for incidence of colorectal cancer or all-cause mortality (table).
CONCLUSION
Faecal occult blood test screening reduces risk of colorectal cancer mortality.
ABSTRACTED FROM
Hewitson P,
University of Nottingham, Nottingham, UK
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
